Lineage Cell Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Lineage Cell Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- LCTX
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0000876343
Board of directors
-
Alfred D. Kingsley · Director · ChairmanSince 2023
-
Angus C. Russell · DirectorSince 2023
-
Anula Jayasuriya · DirectorSince 2023
-
Brian M. Culley · Director · President and CEOSince 2023
-
Deborah J. Andrews · DirectorSince 2023
-
Dipti Amin · DirectorSince 2023
-
Don M. Bailey · DirectorSince 2023
-
Michael H. Mulroy · DirectorSince 2023
-
Neal C. Bradsher · DirectorSince 2023
Chief executives
Brian M. Culley
· President and CEO
Dates unknown
Board connections
3 of this board's directors also sit on 3 other boards.
- via Alfred D. Kingsley
- via Anula Jayasuriya
- via Angus C. Russell
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 11, 2025 | Samuel George A. III Officer (General Counsel) | Option exercise | +6,076 | — | — |
| Feb 11, 2025 | Brian M. Culley Director, Officer (President and CEO) | Option exercise | +31,249 | — | — |
| Feb 11, 2025 | Samuel George A. III Officer (General Counsel) | Shares withheld for tax | −2,440 | $0.65 | $1,586 |
| Feb 11, 2025 | Brian M. Culley Director, Officer (President and CEO) | Shares withheld for tax | −12,547 | $0.65 | $8,156 |
| Jan 27, 2025 | Neal C. Bradsher Director, 10% owner | Open-market purchase | +7,894,737 | $0.76 | $6,000,000 |
| Jan 27, 2025 | Neal C. Bradsher Director, 10% owner | Open-market purchase | +0 | — | — |
| Nov 26, 2024 | Howe Jill Ann Officer (Chief Financial Officer) | Open-market purchase | +15,000 | $0.59 | $8,850 |
| Nov 26, 2024 | Samuel George A. III Officer (General Counsel) | Open-market purchase | +15,000 | $0.60 | $9,000 |
| Nov 22, 2024 | Michael H. Mulroy Director | Open-market purchase | +40,000 | $0.57 | $22,800 |
| Nov 21, 2024 | Brian M. Culley Director, Officer (President and CEO) | Open-market purchase | +40,000 | $0.60 | $24,000 |
| Aug 16, 2024 | Howe Jill Ann Officer (Chief Financial Officer) | Open-market purchase | +10,500 | $0.89 | $9,345 |
| May 24, 2024 | Brian M. Culley Director, Officer (President and CEO) | Open-market purchase | +10,000 | $1.05 | $10,500 |
| Feb 11, 2024 | Samuel George A. III Officer (General Counsel/Secretary) | Option exercise | +6,076 | — | — |
| Feb 11, 2024 | Brian M. Culley Director, Officer (President and CEO) | Option exercise | +31,249 | — | — |
| Feb 11, 2024 | Samuel George A. III Officer (General Counsel/Secretary) | Shares withheld for tax | −2,490 | $1.08 | $2,689 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.